Luminex logo

LMNX - Luminex Share Price

$36.75 0.0  0.1%

Last Trade - 7:14pm

Mid Cap
Market Cap £1.23bn
Enterprise Value £1.15bn
Revenue £301.7m
Position in Universe 2376th / 6857
Unlock LMNX Revenue
Relative Strength (%)
1m +5.52%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -11.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
237.7 270.6 306.6 315.8 334.6 417.4 480 518.7 +11.9%
-1.0 -59.5 +150.2 -73.0 +171.7 +23.6
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, LuminexCorporation revenues increased 25% to $417.4M. Net incomeapplicable to common stockholders excluding extraordinaryitems totaled $14.9M vs. loss of $10.4M. Revenues reflectAssay revenue segment increase of 60% to $211.9M, Otherrevenue segment increase of 74% to $13.6M, Domestic segmentincrease of 29% to $325.8M, Europe segment increase of 33%to $48.6M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


LMNX Revenue Unlock LMNX Revenue

Net Income

LMNX Net Income Unlock LMNX Revenue

Normalised EPS

LMNX Normalised EPS Unlock LMNX Revenue

PE Ratio Range

LMNX PE Ratio Range Unlock LMNX Revenue

Dividend Yield Range

LMNX Dividend Yield Range Unlock LMNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
LMNX EPS Forecasts Unlock LMNX Revenue
Profile Summary

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated June 19, 1998
Public Since March 30, 2000
No. of Shareholders: 477
No. of Employees: 1,325
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite , S&P 600 Small Cap , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 46,251,087
Free Float (0.0%)
Eligible for
LMNX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for LMNX
Upcoming Events for LMNX
Monday 3rd May, 2021 Estimate
Q1 2021 Luminex Corp Earnings Release
Thursday 20th May, 2021
Luminex Corp Annual Shareholders Meeting
Friday 21st May, 2021 Estimate
Luminex Corp Annual Shareholders Meeting
Monday 2nd August, 2021 Estimate
Q2 2021 Luminex Corp Earnings Release
Frequently Asked Questions for Luminex
What is the Luminex share price?

As of 7:14pm, shares in Luminex are trading at $36.75, giving the company a market capitalisation of £1.23bn. This share price information is delayed by 15 minutes.

How has the Luminex share price performed this year?

Shares in Luminex are currently trading at $36.75 and the price has moved by 11.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Luminex price has moved by -24.95% over the past year.

What are the analyst and broker recommendations for Luminex?

Of the analysts with advisory recommendations for Luminex, there are there are currently 0 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Luminex is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Luminex next release its financial results?

Luminex is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Luminex dividend yield?

The Luminex dividend yield is 1.01% based on the trailing twelve month period.

Does Luminex pay a dividend?

Last year, Luminex paid a total dividend of 0.37, and it currently has a trailing dividend yield of 1.01%. Looking ahead, Luminex has not announced an ex-dividend date yet.

When does Luminex next pay dividends?

Luminex has yet to annouce their ex-dividend date. The historic dividend yield on Luminex shares is currently 1.01%.

How do I buy Luminex shares?

To buy shares in Luminex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Luminex?

Shares in Luminex are currently trading at $36.75, giving the company a market capitalisation of £1.23bn.

Where are Luminex shares listed? Where are Luminex shares listed?

Here are the trading details for Luminex:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: LMNX
What kind of share is Luminex?

Based on an overall assessment of its quality, value and momentum, Luminex is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Luminex share price forecast 2021?

Shares in Luminex are currently priced at $36.75. At that level they are trading at 6.02% premium to the analyst consensus target price of 0.00.

Analysts covering Luminex currently have a consensus Earnings Per Share (EPS) forecast of 0.882 for the next financial year.

How can I tell whether the Luminex share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Luminex. Over the past six months, the relative strength of its shares against the market has been 40.12%. At the current price of $36.75, shares in Luminex are trading at 29.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Luminex PE Ratio?

The Luminex PE ratio based on its reported earnings over the past 12 months is 0.113k. The shares are currently trading at $36.75.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Luminex?

Luminex's management team is headed by:

Jimmy Kever - IND
Harriss Currie - CFO
Thomas Erickson - IND
Edward Ogunro - LED
Nachum Shamir - CHM
Nancy Fairchild - SVP
Randall Myers - SVP
Richard Rew - SVP
Stephen Eck - IND
Todd Bennett - SVP
Dijuana Lewis - IND
Chuck Collins - SVP
Eric Shapiro - SVP
Who are the major shareholders of Luminex?

Here are the top five shareholders of Luminex based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 15.12% (6.99m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 11.31% (5.23m shares)
iShares Core S&P Small-Cap ETF Mutual Fund
Percentage owned: 6.26% (2.90m shares)
RGM Capital, LLC Hedge Fund
Percentage owned: 5.84% (2.70m shares)
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund
Percentage owned: 3.98% (1.84m shares)
Similar to LMNX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.